Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Limited Liability Company "Promomed Rus" currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, LEWIS, PATRICK T, who is the busiest examiner for the portfolio. The prosecution is conducted within a distinct art unit, ensuring that the application is reviewed by a department specialized in the company's technology area.
Having LEWIS, PATRICK T as the only examiner responsible for the pending action allows for a unified and consistent prosecution strategy. The practitioner can tailor their arguments to the specific examination style and preferences of the busiest examiner. This level of concentration within the Biotechnology & Pharmaceuticals sector can lead to more predictable outcomes during the patent review process.
The oversight of the pending office action by a distinct art unit indicates a focused approach to securing intellectual property protection. By understanding the specific requirements of the busiest examiner and the art unit, the company can better prepare its responses to the patent office. Monitoring the progress of the pending action is essential for maintaining a successful patent portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEWIS, PATRICK T | 1 | 74.0% | +14.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717786 | NOVEL CRYSTALLINE FORM OF [(2R,3S,4R,5R)-3,4-DIHYDROXY-5-[4-(HYDROXYAMINO)-2- OXOPYRIMIDIN-1-YL]OXOLAN-2-YL]METHYL-2-METHYLPROPANOATE | LEWIS, PATRICK T | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717786 | NOVEL CRYSTALLINE FORM OF [(2R,3S,4R,5R)-3,4-DIHYDROXY-5-[4-(HYDROXYAMINO)-2- OXOPYRIMIDIN-1-YL]OXOLAN-2-YL]METHYL-2-METHYLPROPANOATE | LEWIS, PATRICK T | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18717786 | NOVEL CRYSTALLINE FORM OF [(2R,3S,4R,5R)-3,4-DIHYDROXY-5-[4-(HYDROXYAMINO)-2- OXOPYRIMIDIN-1-YL]OXOLAN-2-YL]METHYL-2-METHYLPROPANOATE | LEWIS, PATRICK T | 1691 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLimited Liability Company "Promomed Rus" has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Patrick T Lewis has the most, with 1 of Limited Liability Company "Promomed Rus"'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
